Aoxiang Pharmaceutical's 2025 Performance Report of the Audit Committee of the Board of Directors
Zhejiang Aoxiang Pharmaceutical Co., Ltd.
2025 Duty Performance Report of the Audit Committee of the Board of Directors
In accordance with relevant regulations such as the "Code of Corporate Governance for Listed Companies", "Stock Listing Rules of the Shanghai Stock Exchange", "Self-Regulatory Guidelines for Listed Companies of the Shanghai Stock Exchange No. 1 - Standardized Operations", "Articles of Association", "Working Rules of the Audit Committee of the Board of Directors" and other relevant regulations, the Audit Committee of the Board of Directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") performed its duties diligently and diligently in 2025, performed its duties conscientiously and prudently, and effectively safeguarded the legitimate rights and interests of the company and all shareholders. The performance report of the Audit Committee of the Board of Directors in 2025 is now as follows:
1. Basic information of the Audit Committee
The Audit Committee of the fourth session of the board of directors of the company consists of three directors, namely independent director Mr. Luo Mingmin, independent director Mr. Yang Lirong and director Mr. Liu Yu. The chairman of the committee is Mr. Luo Mingmin, an independent director with accounting professional qualifications, which complies with the regulations of the Shanghai Stock Exchange and the requirements of relevant systems.
2. Audit Committee Meeting Convening Situation
In 2025, the Audit Committee held a total of 3 meetings. The details are as follows:
(1) On April 28, 2025, the company held the sixth meeting of the Audit Committee of the fourth board of directors, and reviewed and approved the "Proposal on the Company's 2024 Annual Report and its Summary", "The Proposal on the Company's 2024 Internal Control Evaluation Report", "The Proposal on the Renewal of the Audit Institution for 2025", and "The Proposal on the Company's 2025 First Quarter Report".
(2) On August 28, 2025, the company held the seventh meeting of the Audit Committee of the fourth board of directors, and reviewed and approved the "Proposal on the Company's 2025 Semi-Annual Report and its Summary".
(3) On October 30, 2025, the company held the eighth meeting of the Audit Committee of the fourth board of directors, and reviewed and approved the "Proposal on the Company's Third Quarterly Report for 2025" and the "Proposal on the Extension of Some Fund-raising Projects".
3. Main work of the Audit Committee in 2025
(1) Supervise and evaluate the work of external audit institutions
- Evaluate the independence and professionalism of external audit institutions
Tianjian Accounting Firm (Special General Partnership) (hereinafter referred to as "Tianjian") is an external audit institution hired by the company and is qualified to engage in securities-related business. Through the supervision and verification of Tianjian's work during the period of performance of duties, the Audit Committee believes that Tianjian has adhered to its due diligence during its tenure as the company's audit agency, followed the independent, objective and impartial practice standards, completed various audit tasks with due diligence, and better fulfilled the obligations and responsibilities of the audit agency. Furthermore, Tianjian attaches great importance to understanding the company and the company's operating environment, pays attention to the establishment, improvement and implementation of the company's internal controls, and also attaches great importance to maintaining exchanges and communication with the audit committee and independent directors.
- Make recommendations to the board of directors for the renewal of the external audit agency
In view that Tianjian Certified Public Accountants (Special General Partnership) has adhered to its due diligence in providing audit services to the company, followed independent, objective and fair practice standards, and completed various audit tasks with due diligence. The sixth meeting of the Audit Committee of the company's fourth board of directors agreed to recommend that the company's board of directors continue to re-appoint Tianjian Accounting Firm (Special General Partnership) as the company's audit agency for 2025.
- Discuss and communicate relevant audit matters with external audit institutions
During the reporting period, the Audit Committee, in accordance with relevant regulations such as the "Code of Corporate Governance for Listed Companies", "Working Rules of the Audit Committee of the Board of Directors" and the requirements of the company's board of directors, coordinated the company's management, audit department and relevant departments to communicate and negotiate with Tianjian on the audit plan, audit scope and audit methods, pay attention to the progress of relevant audit work, and ensure the smooth completion of all audit work.
(2) Review the company’s financial reports and express opinions
During the reporting period, we carefully reviewed the company's financial report and believed that the company's financial report was true, complete and accurate. There were no relevant frauds, malpractices and material misstatements. There were no adjustments for major accounting errors, major changes in accounting policies and estimates, matters involving important accounting judgments, or matters that resulted in non-standard unqualified audit reports.
(3) Guiding the company’s internal audit work
During the reporting period, in accordance with the provisions of the company's "Internal Audit System" and in light of the company's actual situation, the Audit Committee carefully reviewed the company's internal audit work plan, actively urged the company's audit department to strictly implement the internal audit work plan, guided the company's internal audit work to be carried out in a normal and orderly manner, and provided guiding opinions on the problems discovered by the internal audit. After reviewing the internal audit work report, no major problems were found in the internal audit work.
(4) Evaluate the effectiveness of internal controls
The company has established a relatively complete corporate governance structure and governance system in strict accordance with the requirements of the Company Law, Securities Law and other laws and regulations as well as the relevant regulations of the China Securities Regulatory Commission and Shanghai Stock Exchange. During the reporting period, the company strictly implemented various laws, regulations, rules, company articles of association and internal management systems, and the shareholders' meeting, board of directors and management operated in a standardized manner, effectively protecting the legitimate rights and interests of the company and shareholders. We believe that the actual operation of the company's internal control complies with the requirements of the governance standards for listed companies issued by the China Securities Regulatory Commission.
4. Overall evaluation
In 2025, in accordance with the requirements of relevant laws and regulations and the company's "Working Rules of the Audit Committee of the Board of Directors", we performed the duties of the audit committee with due diligence and diligence, effectively and efficiently supervised the external audit of listed companies, guided the company's internal audit work, and provided true, prepared and complete financial reports.
In 2026, we will continue to uphold the spirit of loyalty, diligence, prudence, responsibility and responsibility to the company and all shareholders, faithfully perform the corresponding duties of the audit committee, further strengthen the communication between the company's external audit, internal audit, and operating management, improve professionalism and decision-making capabilities, provide a basis for the company's board of directors to make scientific decisions, better safeguard the legitimate rights and interests of the company and all shareholders, and play a positive role in the company's sustainable, stable and healthy development.
(No text below)
(This page has no text, but is the signature page of the 25-year performance report of the Audit Committee of the Board of Directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd.
)
Signatures of all members of the Audit Committee
:
Fierce Luo Mingmin Yang Lirong Liu Yu
⒛ April 27, 2026 (This page has no text, but is the signature page of the 25-year Audit Committee Performance Report of the Board of Directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd.
)
Signatures of all members of the Audit Committee
:
Liao Yao
Luo Mingmin Yang Lirong Liu Yu
2026+4E278